THE DEAL, AT A GLANCE
From the announcementClaris Bio
01What it doesIMAGE C/O LIFESCI COMMUNICATIONS Claris Biotherapeutics is setting its sights on a breakthrough in ophthalmology.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Samsara Biocapital, Catalio Capital Management, Adage Capital Management, Sofinnova InvestmentsFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedClaris Bio raised $118M Series B, announced 2026-07-29From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersClaris Bio is financing a late-stage ophthalmology program focused on blinding corneal disease, an area described as receiving relatively little attention versus retina…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Claris Bio · Financing Record
Explore source-linked visual explanations for Claris Bio. Unsupported claims are withheld while source review continues.
Record 9272 · Recorded date: 2026-07-29
What it does
Claris Bio is dedicated to advancing transformative therapies for sight-threatening conditions where limited or no treatment options exist.
Source: clarisbio.com ↗